PMID- 30573970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced 
      squamous cell carcinoma of the lung.
PG  - 8565-8573
LID - 10.2147/OTT.S161506 [doi]
AB  - BACKGROUND: The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: 
      NCT01523587) identified significant improvements in progression-free survival 
      (PFS), overall survival (OS), and patient-reported outcomes (PROs) with 
      second-line afatinib vs erlotinib in patients with advanced squamous cell 
      carcinoma (SCC) of the lung. MATERIALS AND METHODS: We conducted a post hoc 
      analysis of data for patients in LUX-Lung 8 from mainland China (n=67). Compared 
      with erlotinib, afatinib reduced the risk of disease progression or death (PFS) 
      in the Chinese subgroup by 30% (HR=0.70; 95% CI: 0.38-1.27). RESULTS: The risk of 
      death was reduced by 31% (HR=0.69; 95% CI: 0.39-1.21). The proportion of Chinese 
      patients with improvements in PROs also favored afatinib vs erlotinib (global 
      health status/quality of life [QoL], 52.8% vs 29.6%, P=0.072; dyspnea, 47% vs 
      26%, P=0.091; "dyspnea walked", 44% vs 15%, P=0.017; QoL rate, 53% vs 26%, 
      P=0.037). DISCUSSION: While this analysis was not powered to demonstrate 
      differences compared to the overall trial population (OTP), and there were some 
      differences in baseline characteristics (eg, the proportion of patients aged >/=65 
      years old), the benefits of afatinib treatment in Chinese patients with SCC of 
      the lung appeared to be at least comparable to that observed in LUX-Lung 8. As 
      with the OTP, the most common adverse events (AEs) with afatinib in the Chinese 
      subgroup were diarrhea and rash/acne, and the incidence and type of the most 
      frequently occurring AEs were similar. CONCLUSION: The results suggest that 
      afatinib represents a feasible treatment option for Chinese patients with 
      advanced SCC of the lung following progression on platinum-based chemotherapy.
FAU - Lu, Shun
AU  - Lu S
AD  - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai, China, shun_lu@hotmail.com.
FAU - Li, Wei
AU  - Li W
AD  - Cancer Center, First Hospital of Jilin University, Changchun, China.
FAU - Zhou, Caicun
AU  - Zhou C
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China.
FAU - Hu, Cheng-Ping
AU  - Hu CP
AD  - Department of Respiratory Medicine, Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Qin, Shukui
AU  - Qin S
AD  - People's Liberation Army Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, 
      China.
FAU - Cheng, Gang
AU  - Cheng G
AD  - Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, 
      Beijing, China.
FAU - Feng, Jifeng
AU  - Feng J
AD  - Department of Internal Medicine, Jiangsu Provincial Tumor Hospital, Nanjing, 
      China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Internal Medicine, Capital Medical University, Beijing, China.
AD  - Peking University School of Oncology, Beijing Cancer Hospital, Beijing, China.
FAU - Cseh, Agnieszka
AU  - Cseh A
AD  - Department of Medical Affairs, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, 
      Austria.
FAU - Peil, Barbara
AU  - Peil B
AD  - Biostatistics, Boehringer Ingelheim Pharma GmbH & Co. KG. Ingelheim, Germany.
FAU - Gibson, Neil
AU  - Gibson N
AD  - Translational Medicine and Clinical Oncology, Boehringer Ingelheim Pharma GmbH & 
      Co. KG. Biberach, Germany.
FAU - Ehrnrooth, Eva
AU  - Ehrnrooth E
AD  - Division of Oncology, Boehringer Ingelheim, Danmark A/S, Copenhagen, Denmark.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01523587
PT  - Journal Article
DEP - 20181130
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6292388
OTO - NOTNLM
OT  - Chinese patients
OT  - NSCLC
OT  - Phase III
OT  - afatinib
OT  - second-line
OT  - squamous cell carcinoma
COIS- Disclosure CZ reports lecture fees from AstraZeneca, Boehringer Ingelheim, Eli 
      Lilly, Roche, and Sanofi. AC, BP, NG, and EE report employment by Boehringer 
      Ingelheim. The authors report no other conflicts of interest in this work.
EDAT- 2018/12/24 06:00
MHDA- 2018/12/24 06:01
PMCR- 2018/11/30
CRDT- 2018/12/22 06:00
PHST- 2018/12/22 06:00 [entrez]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2018/12/24 06:01 [medline]
PHST- 2018/11/30 00:00 [pmc-release]
AID - ott-11-8565 [pii]
AID - 10.2147/OTT.S161506 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Nov 30;11:8565-8573. doi: 10.2147/OTT.S161506. 
      eCollection 2018.